Related references
Note: Only part of the references are listed.Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy
Yuang Chen et al.
NATURE NANOTECHNOLOGY (2023)
PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing γδ T cells
Sarah C. Edwards et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2022)
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
John D. Powderly et al.
ONCOLOGIST (2022)
Development of a novel formulation method to prepare liposomal Epacadostat
Sahar Tahaghoghi-Hajghorbani et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen et al.
NATURE MEDICINE (2021)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy
Zhiren Wang et al.
NATURE NANOTECHNOLOGY (2021)
Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth
Thuy Phan et al.
CANCER GENE THERAPY (2020)
Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy
Yijia Liu et al.
BIOMATERIALS (2020)
Co -delivery of doxorubicin and epacadostat via heparin coated pH -sensitive to the metastasis of melanoma
Yi Chen et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Echoes of a failure: what lessons can we learn?
Vernon K. Sondak et al.
LANCET ONCOLOGY (2019)
Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer
Qianming Du et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Qian Chen et al.
NATURE NANOTECHNOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair et al.
FRONTIERS IN IMMUNOLOGY (2019)
A patent review of IDO1 inhibitors for cancer
Jae Eun Cheong et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
The expanding role of prodrugs in contemporary drug design and development
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice
Vinay Dhiman et al.
BIOMEDICAL CHROMATOGRAPHY (2017)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Chao Wang et al.
NATURE BIOMEDICAL ENGINEERING (2017)
In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
The importance of hydrogen bonding in sphingomyelin's membrane interactions with co-lipids
J. Peter Slotte
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2016)
Immune-checkpoint blockade - durable cancer control
Elizabeth I. Buchbinder et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Functional evidence for TCR-intrinsic specificity for MHCII
Heather L. Parrish et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Yichao Chen et al.
NATURE COMMUNICATIONS (2016)
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
Anja Derer et al.
FRONTIERS IN IMMUNOLOGY (2016)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells
Xian-Feng Wang et al.
CELLULAR IMMUNOLOGY (2014)
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
Brian Higgins et al.
CLINICAL CANCER RESEARCH (2014)
The Effects of Ultra-High Dose Rate Proton Irradiation on Growth Delay in the Treatment of Human Tumor Xenografts in Nude Mice
O. Zlobinskaya et al.
RADIATION RESEARCH (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Sphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function
Roberto Martinez-Beamonte et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth
Alice Hervieu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dacarbazine mediate antimelanoma effects via NK cells
Alice Hervieu et al.
ONCOIMMUNOLOGY (2013)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
Qiyi Zhao et al.
JOURNAL OF IMMUNOLOGY (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
H. Cabral et al.
NATURE NANOTECHNOLOGY (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine
Daryl C. Drummond et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
Prodrugs: design and clinical applications
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
K. Ino et al.
BRITISH JOURNAL OF CANCER (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations
MJW Johnston et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Share Paper
